Patent ID: 11883485
Assignee: FRED HUTCHINSON CANCER CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 1:
2. The method of claim 1, wherein the 426c core HIV-1 Env comprises: (i) mutations at N460D, N463D, S278R, and G471S; or N460D, N463D, S278R, G471S, V65C, and S115C; (ii) removal of the V1 loop and the V2 loop; (iii) replacement of the V3 loop with a flexible linker; and (iv) an N-terminal truncation; wherein the 426c core HIV-1 Env does not have a mutation at position 276 and wherein residue numbering is based on the prototypic HIV-1 isolate HxB2.